Evidence map›Paper›PMID 31356193›Full record

ArticleCancer biomarkers : section A of Disease markers2019

Serum thrombomodulin as a metastatic and prognostic marker in soft tissue sarcomas.

Kunihiro Asanuma, Tomoki Nakamura, Yumiko Asanuma, Takuya Kakimoto, Yuki Yada, Tomohito Hagi, Kouji Kita, Akihiko Matsumine, Akihiro Sudo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Diagnostic Value of Coagulation-Fibrinolysis Biomarkers for Metastasis in Lung, Ovarian, Breast, and Colorectal Cancers.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Kunihiro AsanumaDepartment of Orthopedic Surgery, Mie University School of Medicine, Tsu, Mie, Japan.
Tomoki NakamuraDepartment of Orthopedic Surgery, Mie University School of Medicine, Tsu, Mie, Japan.
Yumiko AsanumaDepartment of Orthopedic Surgery, Mie University School of Medicine, Tsu, Mie, Japan.
Takuya KakimotoDepartment of Orthopedic Surgery, Mie University School of Medicine, Tsu, Mie, Japan.
Yuki YadaDepartment of Orthopedic Surgery, Mie University School of Medicine, Tsu, Mie, Japan.
Tomohito HagiDepartment of Orthopedic Surgery, Mie University School of Medicine, Tsu, Mie, Japan.
Kouji KitaDepartment of Orthopedic Surgery, Mie University School of Medicine, Tsu, Mie, Japan.
Akihiko MatsumineDepartments of Orthopedic Surgery, Faculty of Medical Sciences, University of Fukui, Eiheiji, Fukui, Japan.
Akihiro SudoDepartment of Orthopedic Surgery, Mie University School of Medicine, Tsu, Mie, Japan.
Mie University · JPUniversity of Fukui · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThrombomodulin (TM) has multiple biological functions and modulates not only anti-coagulation, but also cell proliferation, adhesion, and anti-inflammation activities. The main function of TM is to activate the anticoagulant pathway of protein C. Soluble TM is related to metastasis by its inactivation of thrombin.

objectivesTo clarify the correlation between serum TM levels and clinicopathological parameters.

methodsThe plasma TM levels (FU/ml) of 135 primary soft tissue tumors (benign, 67; soft tissue sarcoma (STS), 68) were measured before biopsy or treatment. TM levels were analyzed and compared to various clinicopathological parameters. Log-rank test and Cox proportional analysis were used to evaluate recurrence-free survival, metastasis-free survival, and overall survival.

resultsSTS tumors had significantly higher TM values (15.9) than benign tumors (13.7) (p= 0.0138). 5-year MFS was 81.1% in low TM and 40.0% in high TM (p= 0.00671), and 5-year OS was 85.5% in low and 52.5% in high TM in grades 1-3 (p= 0.0673). In multivariate COX proportional analysis, high-TM showed a significant difference (MFS: HR 4.37, p= 0.0147; OS: HR 3.60, p= 0.0557) in grades 1-3.

conclusionsWe demonstrated that a high level of soluble TM has the potential to be a significant predictor of metastasis and poor prognosis in STS patients. TM is a candidate molecular marker for high metastatic potential and can be clinically useful for guiding therapeutic strategy.

Indexed as

AdolescentAdultAgedAged, 80 and overBiomarkers, TumorChildFemaleFollow-Up StudiesHumansLymphatic MetastasisMaleMiddle AgedPrognosisRetrospective StudiesSarcomaSoft Tissue NeoplasmsBiomarkers, TumorTHBD protein, humanThrombomodulinmetastasisprognosissoft tissue sarcomasoft tissue tumorThrombomodulin

Identifiers

PMID31356193
PMCPMC12826432
OpenAlexW2962796543

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.